Vicarious Surgical Inc (NYSE:RBOT – Get Rating) has received a consensus recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $13.20.
A number of equities research analysts recently commented on RBOT shares. Zacks Investment Research lowered Vicarious Surgical from a “buy” rating to a “hold” rating in a research report on Saturday. Piper Sandler decreased their price target on Vicarious Surgical from $7.00 to $5.00 in a research report on Tuesday, May 10th.
In other Vicarious Surgical news, CTO Sammy Khalifa sold 6,830 shares of the company’s stock in a transaction on Thursday, April 14th. The stock was sold at an average price of $4.08, for a total transaction of $27,866.40. Following the transaction, the chief technology officer now owns 136,413 shares of the company’s stock, valued at approximately $556,565.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Adam David Sachs sold 8,537 shares of the company’s stock in a transaction on Monday, March 28th. The stock was sold at an average price of $4.23, for a total value of $36,111.51. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,842 shares of company stock worth $152,359.
Shares of RBOT stock traded up $0.35 during trading hours on Thursday, hitting $4.02. The company had a trading volume of 15,533 shares, compared to its average volume of 371,233. Vicarious Surgical has a 12 month low of $3.05 and a 12 month high of $15.79. The firm’s fifty day moving average is $4.67 and its 200 day moving average is $7.57.
Vicarious Surgical (NYSE:RBOT – Get Rating) last released its quarterly earnings data on Thursday, March 3rd. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.04). Sell-side analysts forecast that Vicarious Surgical will post -0.6 EPS for the current year.
Vicarious Surgical Company Profile (Get Rating)
Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
- Get a free copy of the StockNews.com research report on Vicarious Surgical (RBOT)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
- Beware The Rebound In Home Depot
Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.